ARTICLE | Clinical News
Eltoprazine: Phase IIb halted
October 12, 2015 7:00 AM UTC
Amarantus halted enrollment in a double-blind, placebo-controlled, 4-way crossover, international Phase IIb trial of oral eltoprazine in about 60 patients due to an “internal prioritization.” The company expects to restart enrollment next year. Amarantus has exclusive, worldwide rights, excluding countries in Asia, to eltoprazine from PsychoGenics (see BioCentury, Jan. 20, 2014). ...